MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » EOFlow invests $7.7B in Pharmeo subsidiary for non-insulin drug delivery development

EOFlow invests $7.7B in Pharmeo subsidiary for non-insulin drug delivery development

By

EOFlow EOPatch insulin patch
[Image from the EOFlow website]
EOFlow announced today that it plans to invest $7.7 billion (9.9 billion Korean Won) in its wholly-owned Pharmeo subsidiary.

The investment aims to advance R&D and commercialization of non-insulin drugs with EOFlow’s wearable drug delivery system.

Get the full story at our sister site, Drug Delivery Business News.

More recent news

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].